REIMAGINE - 美泊利单抗在严重哮喘治疗中实现临床缓解的真实世界评估,一项前瞻性研究 (REIMAGINE)
一项前瞻性、真实世界、干预性研究,旨在评估美泊利单抗对严重哮喘参与者实现临床缓解的影响
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
研究概览
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T3B0M3
- GSK Investigational Site
-
Calgary、Alberta、加拿大
- GSK Investigational Site
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R3L 1Z5
- GSK Investigational Site
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 1E2
- GSK Investigational Site
-
-
-
-
-
Bonn、德国、53119
- GSK Investigational Site
-
Hohenstein-Ernsttal、德国、9337
- GSK Investigational Site
-
Schleswig、德国、53123
- GSK Investigational Site
-
-
Hesse
-
Darmstadt、Hesse、德国、64283
- GSK Investigational Site
-
Frankfurt am Main、Hesse、德国、60389
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Aachen、North Rhine-Westphalia、德国、52074
- GSK Investigational Site
-
-
-
-
-
Genova、意大利、16132
- GSK Investigational Site
-
Monserrato CA、意大利、09042
- GSK Investigational Site
-
Naples、意大利、80131
- GSK Investigational Site
-
Pieve Di Soligo TV、意大利、131044
- GSK Investigational Site
-
Roma、意大利、00128
- GSK Investigational Site
-
Roma、意大利、161
- GSK Investigational Site
-
Rozzano、意大利、20089
- GSK Investigational Site
-
Verona、意大利、37126
- GSK Investigational Site
-
-
-
-
-
Gifu、日本、509-6134
- GSK Investigational Site
-
Kagawa、日本、760-0018
- GSK Investigational Site
-
Tokyo、日本、142-8666
- GSK Investigational Site
-
Tokyo、日本、173-8606
- GSK Investigational Site
-
Tokyo、日本、105-0003
- GSK Investigational Site
-
-
-
-
-
Kortrijk、比利时、8500
- GSK Investigational Site
-
Liège、比利时、4000
- GSK Investigational Site
-
-
-
-
-
Brest、法国、29200
- GSK Investigational Site
-
Cannes、法国、06614
- GSK Investigational Site
-
Lille、法国、59000
- GSK Investigational Site
-
Lyon、法国、69004
- GSK Investigational Site
-
Strasbourg、法国、67091
- GSK Investigational Site
-
Toulouse、法国、31059
- GSK Investigational Site
-
-
-
-
-
?Od?、波兰、90-153
- GSK Investigational Site
-
Gdansk、波兰、80-214
- GSK Investigational Site
-
Lodz、波兰、92-213
- GSK Investigational Site
-
-
-
-
California
-
La Jolla、California、美国、92037
- GSK Investigational Site
-
Newport Beach、California、美国、92663
- GSK Investigational Site
-
-
Colorado
-
Aurora、Colorado、美国、71105
- GSK Investigational Site
-
Colorado Springs、Colorado、美国、80923
- GSK Investigational Site
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- GSK Investigational Site
-
-
Florida
-
Homestead、Florida、美国、33032-8185
- GSK Investigational Site
-
Jacksonville、Florida、美国、32209
- GSK Investigational Site
-
Miami、Florida、美国、33125
- GSK Investigational Site
-
Plantation、Florida、美国、33317
- GSK Investigational Site
-
-
Georgia
-
Adairsville、Georgia、美国、30103
- GSK Investigational Site
-
Columbus、Georgia、美国、31904
- GSK Investigational Site
-
-
Kentucky
-
Lexington、Kentucky、美国、40509-1801
- GSK Investigational Site
-
Owensboro、Kentucky、美国、42301
- GSK Investigational Site
-
-
Louisiana
-
New Orleans、Louisiana、美国、34452
- GSK Investigational Site
-
-
Maryland
-
Glenn Dale、Maryland、美国、20769
- GSK Investigational Site
-
Towson、Maryland、美国、21204
- GSK Investigational Site
-
-
Michigan
-
Ann Arbor、Michigan、美国、48103
- GSK Investigational Site
-
-
Minnesota
-
Linwood、Minnesota、美国、55092
- GSK Investigational Site
-
Rochester、Minnesota、美国、55905-0001
- GSK Investigational Site
-
-
Nevada
-
Henderson、Nevada、美国、89052-5015
- GSK Investigational Site
-
-
New York
-
Rochester、New York、美国、14607
- GSK Investigational Site
-
Schenectady、New York、美国、12308
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19140
- GSK Investigational Site
-
Philadelphia、Pennsylvania、美国、19141
- GSK Investigational Site
-
-
South Carolina
-
Union、South Carolina、美国、29379-7409
- GSK Investigational Site
-
-
Texas
-
Cypress、Texas、美国、77429-1439
- GSK Investigational Site
-
Kerrville、Texas、美国、78028
- GSK Investigational Site
-
McKinney、Texas、美国、75069
- GSK Investigational Site
-
-
-
-
-
Barcelona、西班牙、08025
- GSK Investigational Site
-
Girona、西班牙、17005
- GSK Investigational Site
-
Valencia、西班牙、46015
- GSK Investigational Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by their physician for the treatment of asthma, as per local label. NUCALA can be initiated up to 7 days prior to study enrollment.
- No NUCALA use in the 6 months prior to enrollment.
- Participants with greater than or equal to (≥)60 percentage (%) predicted forced expiratory volume in 1 second (FEV1) and less than or equal to (≤)4 exacerbations per year, as confirmed by the physician.
- Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria).
- Written informed consent
Exclusion Criteria:
- Investigator concerns about participant's willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare)
- Participants currently on maintenance OCS or intramuscular corticosteroids.
- Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment
- Participants participating in an interventional study with a treatment intervention
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Group 1
Participants with a clinical diagnosis of Severe asthma prescribed Mepolizumab as part of routine care. |
Mepolizumab will be prescribed based on physician decision. Lung function via spirometry will be collected. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage (%) of Participants Achieving 4-Component Clinical Remission
大体时间:At month 12
|
4-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an Asthma Control Test (ACT) (d) No clinically significant deterioration of lung function. |
At month 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Annualized Rates of Clinically Significant Asthma Exacerbations (CSE) and CSE Leading to Hospitalization/ Emergency Room (ER) Visits
大体时间:At month 12
|
CSE is defined as a deterioration in asthma requiring (1) the initiation of systemic corticosteroids and/or (2) an ER visit and/or hospital admission. |
At month 12
|
|
Percentage of Participants Achieving OCS Sparing Remission
大体时间:At month 12
|
OCS sparing is defined as (a) No clinically significant asthma exacerbations during the period of interest (b) No OCS use for asthma at the time point of interest. |
At month 12
|
|
Percentage of Participants Achieving 3-Component Clinical Remission
大体时间:At month 12
|
3-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an ACT |
At month 12
|
|
Mean Change from Baseline in Mini-Asthma Quality of Life Questionnaire (AQLQ) Overall Score
大体时间:Baseline and at month 12
|
The mini-AQLQ overall score is a reduced version of the AQLQ which includes 15 items. The minimally clinically important difference (MCID) is 0.5. The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability |
Baseline and at month 12
|
合作者和调查者
调查人员
- 研究主任:GSK Clinical Trials、GlaxoSmithKline
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 219871
- 2023 (美国 NIH 拨款/合同)
- 2023-509026-21-00 (注册表标识符:CTIS (EU))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD 共享时间框架
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD 共享访问标准
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.